FMP

FMP

Enter

MEDCL.PA - MedinCell S.A.

Financial Summary of MedinCell S.A.(MEDCL.PA), MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a techno

photo-url-https://financialmodelingprep.com/image-stock/MEDCL.PA.png

MedinCell S.A.

MEDCL.PA

EURONEXT

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.

13.78 EUR

0.16 (1.16%)

About

ceo

Mr. Christophe Douat

sector

Healthcare

industry

Biotechnology

website

https://www.medincell.com

exchange

EURONEXT

Description

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraceptio...

CIK

N/A

ISIN

FR0004065605

CUSIP

F6104D107

Address

3 rue des Frères Lumière

Phone

33 4 67 02 13 67

Country

FR

Employee

138

IPO Date

Oct 8, 2018

Summary

CIK

-

Exchange

EURONEXT

Industry

Biotechnology

Sector

Healthcare

CUSIP

F6104D107

ISIN

FR0004065605

Country

FR

Price

13.78

Beta

1.1

Volume Avg.

121.89k

Market Cap

400.45M

Shares

-

52-Week

5.25-17.5

DCF

0

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-16.02

P/B

-

Website

https://www.medincell.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest MEDCL.PA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep